GE Healthcare, a leading medical device manufacturer, is reportedly considering the sale of a stake in its China unit, according to a Bloomberg News report on September 18, 2025. The potential transaction could value the assets at several billion dollars, though discussions remain in preliminary stages, and no definitive decisions have been reached. A company spokesperson declined to comment on market rumors but reiterated GE Healthcare’s commitment to serving patients in China, one of the world’s largest healthcare markets. The move comes amid growing challenges for U.S. companies in China, including political tensions, intense domestic competition, and slowing economic growth. A recent survey by the American Chamber of Commerce in Shanghai revealed that U.S. companies’ five-year business outlook in China has plummeted to a record low of 41%. GE Healthcare has faced significant hurdles in the region, with a 15% decline in revenue in 2024 attributed to weakened sales and tariff impacts. In July 2025, the company’s CFO indicated plans to shift production capacity to more tariff-friendly locations. Despite these challenges, GE Healthcare’s shares rose 1.4% in premarket trading following the news.